Predictors for contralateral prophylactic mastectomy in breast cancer patients

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 4, 2015, Pages 3748-3764

  Fu, Yun ^a,b   Zhuang, Zhigang ^b   Dewing, Michelle ^a   Apple, Sophia ^a   Chang, Helena ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Shanghai First Maternity and Infant Health Hospital   (China)

Author keywords

Bilateral mastectomy; BRCA mutation; Breast cancer; Contralateral prophylactic mastectomy; Predictors

Indexed keywords

BRCA1 PROTEIN;

ADULT; AGED; BREAST NEOPLASMS; CANCER STAGING; CARCINOMA, DUCTAL, BREAST; CLINICAL DECISION MAKING; FEMALE; GENETICS; HUMAN; MASTECTOMY; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROPHYLACTIC SURGICAL PROCEDURE; RETROSPECTIVE STUDY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BRCA1 PROTEIN; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CLINICAL DECISION-MAKING; FEMALE; HUMANS; MASTECTOMY; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPHYLACTIC SURGICAL PROCEDURES; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84935106598     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.
2. Tuttle TM, Jarosek S, Habermann EB, Arrington A, Abraham A, Morris TJ, Virnig BA. Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol 2009; 27: 1362-1367.
3. Habermann EB, Abbott A, Parsons HM, Virnig BA, Al-Refaie WB, Tuttle TM. Are mastectomy rates really increasing in the United States? J Clin Oncol 2010; 28: 3437-3441.
4. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002; 20: 3628-3636.
5. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb M, Kiel K, Ljung BM, Marcom PK, Mayer IA, McCormick B, Nabell LM, Pierce LJ, Reed EC, Smith ML, Somlo G, Theriault RL, Topham NS, Ward JH, Winer EP, Wolff AC; NCCN Breast Cancer Clinical Practice Guidelines Panel. Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2009; 7: 122-192.
6. Tuttle TM, Habermann EB, Grund EH, Morris TJ, Virnig BA. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol 2007; 25: 5203-5209.
7. McLaughlin CC, Lillquist PP, Edge SB. Surveillance of prophylactic mastectomy: trends in use from 1995 through 2005. Cancer 2009; 115: 5404-5412.
8. King TA, Sakr R, Patil S, Gurevich I, Stempel M, Sampson M, Morrow M. Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J Clin Oncol 2011; 29: 2158-2164.
9. Antoniou A, Pharoah PD, Narod S. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72: 1117-1130.
10. Metcalfe KA, Lubinski J, Ghadirian P. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. J Clin Oncol 2008; 26: 1093-1097.
11. Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van't Veer L, Garber JE, Evans GR, Narod SA, Isaacs C, Matloff E, Daly MB, Olopade OI, Weber BL. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004; 22: 1055-1062.
12. Bevers TB, Armstrong DK, Arun B, Carlson RW, Cowan KH, Daly MB, Fleming I, Garber JE, Gemignani M, Gradishar WJ, Krontiras H, Kulkarni S, Laronga C,Lawton T, Loftus L, Macdonald DJ, Mahoney MC, Merajver SD, Seewaldt V, Sellin RV, Shapiro CL, Singletary E, Ward JH; National Comprehensive Cancer Network (NCCN). Breast cancer risk reduction. J Natl Compr Canc Netw 2007; 5: 676-701.
13. Warner E, Hill K, Causer P. Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol 2011; 29: 1664-1669.
14. Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, Morris E, Pisano E, Schnall M, Sener S, Smith RA, Warner E, Yaffe M, Andrews KS, Russell CA; American Cancer Society Breast Cancer Advisory Group. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007; 57: 75-89.
15. Katipamula R, Degnim AC, Hoskin T, Boughey JC, Loprinzi C, Grant CS, Brandt KR, Pruthi S, Chute CG, Olson JE, Couch FJ, Ingle JN, Goetz MP. Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging. J Clin Oncol 2009; 27: 4082-4088.
16. Miller BT, Abbott AM, Tuttle TM. The influence of preoperative MRI on breast cancer treatment. Ann Surg Oncol 2012; 19: 536-540.
17. Sorbero ME, Dick AW, Beckjord EB, Ahrendt G. Diagnostic breast magnetic resonance imaging and contralateral prophylactic mastectomy. Ann Surg Oncol 2009; 16: 1597-1605.
18. Prabhu R, Godette K, Carlson G, Losken A, Gabram S, Fasola C, O'Regan R, Zelnak A, Torres M. The impact of skin-sparing mastectomy with immediate reconstruction in patients with Stage III breast cancer treated with neoadjuvant chemotherapy and postmastectomy radiation. Int J Radiat Oncol Biol Phys 2012; 82: e587-593.
19. Kronowitz SJ. Current status of implant-based breast reconstruction in patients receiving postmastectomy radiation therapy. Plast Reconstr Surg 2012; 130: 513e-523e.
20. Vandergrift JL, Niland JC, Theriault RL, Edge SB, Wong YN, Loftus LS, Breslin TM, Hudis CA, Javid SH, Rugo HS, Silver SM, Lepisto EM, Weeks JC. Time to adjuvant chemotherapy for breast cancer in National Comprehensive Cancer Network institutions. J Natl Cancer Inst 2013; 105: 104-112.
21. Dragun AE, Pan J, Riley EC, Kruse B, Wilson MR, Rai S, Jain D. Increasing use of elective mastectomy and contralateral prophylactic surgery among breast conservation candidates: a 14-year report from a comprehensive cancer center. Am J Clin Oncol 2013; 36: 375-380.
22. Jagsi R, Jiang J, Momoh AO, Alderman A, Giordano SH, Buchholz TA, Kronowitz SJ, Smith BD. Trends and variation in use of breast reconstruction in patients with breast cancer undergoing mastectomy in the United States. J Clin Oncol 2014; 32: 919-926.
23. Arrington AK, arosek SL, Virnig BA, Habermann EB, Tuttle TM. Patient and surgeon characteristics associated with increased use of contralateral prophylactic mastectomy in patients with breast cancer. Ann Surg Oncol 2009; 16: 2697-2704.
24. Ashfaq A. McGhan LJ, Pockaj BA, Gray RJ, Bagaria SP, McLaughlin SA, Casey WJ 3rd, Rebecca AM, Kreymerman P, Wasif N. Impact of breast reconstruction on the decision to undergo contralateral prophylactic mastectomy. Ann Surg Oncol 2014; 21: 2934-2940.